Cargando…

Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations

Background: The clinical utility of circulating tumor DNA (ctDNA) in the early detection of tumor mutations for targeted therapy and the monitoring of tumor recurrence has been reported. However, the analytical validation of ctDNA assays is required for clinical application. Methods: This study eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Yong Gon, Park, Joonhong, Han, Ji Yoon, Kim, Tae Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298348/ https://www.ncbi.nlm.nih.gov/pubmed/37372399 http://dx.doi.org/10.3390/genes14061219

Ejemplares similares

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay
por: Guo, Qiao-mei, et al.
Publicado: (2019)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer
por: Wu, Zhiwei, et al.
Publicado: (2022)

cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
por: He, Qiong, et al.
Publicado: (2020)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

In silico error correction improves cfDNA mutation calling
por: Kim, Chang Sik, et al.
Publicado: (2019)

Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers
por: Gunning, Alicia, et al.
Publicado: (2023)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays
por: Hallermayr, Ariane, et al.
Publicado: (2023)

Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants
por: Sugasawa, Takehito, et al.
Publicado: (2021)

Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer
por: Liang, Leilei, et al.
Publicado: (2022)

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus
por: Vestergaard, Lau K., et al.
Publicado: (2021)

Evaluation of cfDNA as an early detection assay for dense tissue breast cancer
por: Barbirou, Mouadh, et al.
Publicado: (2022)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Verzè, Michela, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer
por: Ding, Shanshan, et al.
Publicado: (2019)

Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients
por: Boldrin, Elisa, et al.
Publicado: (2019)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples
por: Nesic, Marijana, et al.
Publicado: (2021)

Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
por: Liu, Haiyan E., et al.
Publicado: (2020)

Validating quantitative PCR assays for cfDNA detection without DNA extraction in exercising SLE patients
por: Neuberger, Elmo W. I., et al.
Publicado: (2021)

Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)
por: Garcia, Jessica, et al.
Publicado: (2018)

Liquid biopsy using cfDNA to predict radiation therapy response in solid tumors
por: Cho, Won Kyung, et al.
Publicado: (2023)

Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression
por: Sestokaite, Agne, et al.
Publicado: (2023)

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis
por: Jackson Chornenki, Nicholas L., et al.
Publicado: (2019)

Novel technologies in cfDNA analysis and potential utility in clinic
por: Li, Jie, et al.
Publicado: (2021)

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
por: Gerard, Laura, et al.
Publicado: (2021)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing
por: Medina Diaz, Inga, et al.
Publicado: (2016)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
por: Fujita, Kazutaka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m94umhq70mtke697b9cgm63mqg